Navigation Links
OvaGene Oncology Joins The Gynecologic Oncology Group (GOG) Industry Collaboration Team to Advance Gynecologic Cancer Research
Date:8/4/2010

IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program.  By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely medical centers, universities, and pharmaceutical companies dedicated to advancing the scientific and clinical knowledge of gynecologic cancers.  

OvaGene's mission to improve the quality of life and survival for gynecologic cancer patients is further enhanced by joining this select group.  The Industry Collaboration Team has a limited membership and OvaGene is honored to have been given an opportunity to become a member. By joining the ICT program, OvaGene will gain direct access to oncology leaders and key decision makers in the field gynecologic oncology.  This will facilitate direct communication with the cancer treating physicians about OvaGene's products and diagnostic research capabilities. The valuable feedback provided can help accelerate the development of OvaGene's product pipeline by allowing the company to identify and address unmet clinical needs.

"We are very pleased to be an ICT member," said William Ricketts, Ph.D., Chief Scientific Officer for OvaGene.  "The GOG has one of the largest archived and annotated gynecologic tumor banks.  It is a privilege to be given the opportunity to collaborate with the GOG as a member of the ICT and potentially on studies focused to discover and validate new molecular diagnostics. This will help us bring cl
'/>"/>

SOURCE OvaGene Oncology Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OvaGene Oncology Opens New Innovative Gynecologic Cancer Laboratory and Research Facility
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
7. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
8. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
9. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
10. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
11. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 Research and Markets ( ... "The Corporate Reputation of Pharma - The ... report to their offering. The ... now in its fourth edition. This report contains ... For each annual Corporate Reputation report, the author ...
(Date:4/16/2015)... , April 16, 2015 Vanda Pharmaceuticals Inc. ... on the development and commercialization of products for the ... will release results for the first quarter of 2015 ... The Company will host a conference ... 2015, during which Vanda management will discuss the first ...
(Date:4/16/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... on Tuesday, April 21, 2015, after the close of ... by a conference call with the investment community at ... will be Robert A. Bradway , chairman and ... management team. Live audio of the conference ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... SCOTTSDALE, Ariz., Feb. 14, 2012  Cayenne Medical, Inc., a ... of a $10 million equity financing, with new investor ... MB Venture Partners and Investor Growth Capital. The proceeds ... distribution and to support expansion of its portfolio of ...
... 2012 Leading events organiser UBM Live , a ... of Jim Buckley as the new Brand Director for Informex. ... value chemistry via a comprehensive calendar of conferences and events, ... is run in partnership with the Society of Chemical Manufacturers ...
Cached Medicine Technology:Cayenne Medical Closes $10 Million Capital Raise 2UBM Live Appoints Jim Buckley as Informex Brand Director 2UBM Live Appoints Jim Buckley as Informex Brand Director 3
(Date:4/19/2015)... York (PRWEB) April 19, 2015 New ... Multidistrict Litigation (JPML) indicate that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... in U.S. District Court, District of South Carolina. According ... cases have been filed in the proceeding on behalf ... to their use of the cholesterol-lowering statin. This represents ...
(Date:4/19/2015)... Hanover, MA (PRWEB) April 19, 2015 Family ... Bowling for Brains in Memory of Brad Baddeley ... renowned Brain Aneurysm Foundation. , Bowling for Brains is cheduled ... Bowling located 4700 Dudley Street in Lincoln, Nebraska. Participants may ... from 1:00 to 3:00pm. , The cost is only $4 ...
(Date:4/18/2015)... Carinsurancequotesinfo.com has released a new blog post explaining ... caused by a car accident. , Car insurance ... A policy can pay for car repairs and even ... carry appropriate coverage when they are driving. ... several important riders that offer extra coverage options. One ...
(Date:4/18/2015)... Review of Ophthalmology magazine and Abbot Medical ... program for cataract surgeons attending the American Society of ... eye surgeon Jeffrey L. Martin, MD will serve as ... is the Managing Partner of North Shore Eye Care. ... to lead this year’s discussion on the latest breakthroughs ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3
... 10, 2007 The sleep patterns of patients in ... barely spend any time in the restorative stages of ... physicians have found. , Current clinical-care protocols routinely and ... time when the need for adequate rest is perhaps ...
... Overall Survival Advantage in Elderly Myeloma ... Added to Standard Therapy - Data Presented at ... Dec. 9 Pharmion Corporation (Nasdaq:,PHRM) today announced final ... that the addition of,Thalidomide to standard treatment improves survival ...
... - Two drugs approved for use as second line therapy ... therapy for newly diagnosed patients in two clinical trials, research ... D. Anderson Cancer Center report at the 49th annual meeting ... patients in both trials have a complete cytogenetic response - ...
... Health & Science University Cancer Institute researchers have opened a ... , We are looking under the surface of CML to ... have discovered abnormal cells in the early stem cell population ... clone. These are abnormal cells that are not part of ...
... off going to the doctor or overindulge in unhealthy ... -- The holiday season is also the season for ... of the Vanderbilt Heart and Vascular Institute at Vanderbilt ... Churchwell, a look at a U.S. database of 53 ...
... GA, December 8, 2007 -- Results from two investigational ... bortezomib provide preliminary anti-tumor activity in patients with relapsed ... showed that 10 of 21 (48 percent) evaluable patients ... and bortezomib combination treatment. Data from a second ...
Cached Medicine News:Health News:Physicians seek to improve the quality of sleep in ICU, researchers at UT Southwestern report 2Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 2Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 3Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 4Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 5Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 6Health News:Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75 7Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:OHSU Cancer Institute research discovery opens new window to understanding chronic myeloid leukemia 2Health News:Heart Attacks Peak During the Holidays 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3
... drainage from the ureteropelvic junction to the ... segment with no sideports prevents postoperative narrowing ... of the ureteral wall to the stent. ... one-time use. CAUTION: Periodic evaluation is advised; ...
... Whether you prefer silicone or ... Specialty Stents help promote healing after ... guards against anastomotic stricture, supports the ... the prevention of postoperative leakage. Following ...
... The Max-Blade™ Coagulating Resector is a device that ... This patented design was developed to provide the ... same high quality pathology chip, the approximate speed ... enjoyed with a standard loop but with ...
... Used for stone manipulation and removal in ... the basket to retain its shape following extreme ... stone capture by allowing the basket to open ... the stone. The tipless design reduces the likelihood ...
Medicine Products: